Compare Altria Group Inc (MO) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Tempus AI — how do they compare? Altria Group Inc trades at $71.26 (market cap $119.25B), while Tempus AI trades at $70.28 (market cap $12.58B). The key difference: Altria Group Inc is far larger — about 9.5× Tempus AI's market cap, and Altria Group Inc pays a 6.22% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 154 Days and Tempus AI for 22 Days on average.
| MO | TEM | |
|---|---|---|
Market Cap | $119.25B | $12.58B |
Volume | 11,178,169 | 7,444,569 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $74.92 | $99.28 |
52-Week Low | $54.72 | $41.55 |
Typical Hold Time | 154 Days | 22 Days |
Enterprise Value | $141.46B | $13.21B |
Dividend Yield | 6.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $69.39, up 1.22% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 39% net income margin and a 6.6% dividend yield, though recent earnings have been mixed with two misses in the last four quarters. Cash flow improved in 2025 with net cash flow of $1.33 billion, but the balance sheet carries negative equity of -$2.24 billion due to high liabilities.
The outlook is balanced: analyst consensus is bullish with a $69.71 price target, but risks include regulatory pressures on tobacco, declining margins, and high debt. The dividend appears sustainable from cash flow, yet negative equity and business shrinkage pose long-term concerns for income-focused investors.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
